NewsRamp Psychedelics Podcast

NewsRamp.com

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

  1. May 8

    Silo Pharma Explores Ibogaine for TBI & Neuropsychiatric Conditions

    Silo Pharma Inc. is researching ibogaine-based treatments for traumatic brain injury and related conditions, aiming to address underserved health issues.

    1 min

  2. May 3

    Federal Support Boosts Psychedelic Therapeutics

    Silo Pharma Inc. highlights U.S. federal momentum backing the development of psychedelic-based therapies for mental health and substance use disorders, anticipating innovation in treating conditions such as PTSD and addiction.

    1 min

  3. Apr 29

    Federal Support Boosts Psychedelic Therapeutics

    Silo Pharma Inc. highlights U.S. federal actions advancing the development of psychedelic-based therapies for mental health and substance use disorders, anticipating innovation in PTSD and addiction treatment.

    1 min

  4. Apr 21

    Optimi Health Corp. Ibogaine Initiative

    Optimi Health Corp. launches an Ibogaine Initiative to meet demand for pharmaceutical-grade ibogaine and expand its global strategy in psychedelic therapies, aligning with U.S. regulatory changes.

    1 min

  5. Apr 20

    Psychedelic Therapy Companies Embrace White House Executive Order

    Helus Pharma(TM) and NRx Pharmaceuticals show support for the Executive Order promoting psychedelic therapies, emphasizing research acceleration and patient access.

    2 min

  6. Apr 9

    Advancements in Stress and Depression Treatments in Europe and U.S.

    Silo Pharma Inc. secures European patent for stress prevention methods, while NRx Pharmaceuticals works on ketamine labeling and supply in the U.S.

    2 min

  7. Mar 16

    FDA to Review NRX-100 NDA for Depression Treatment

    NRx Pharmaceuticals receives FDA approval for NRX-100 ketamine formulation for severe depression treatment based on existing clinical trial data, while NeuroThera Labs Inc. collaborates with Clearmind Medicine Inc. to develop a new non-hallucinogenic therapy for major depressive disorder.

    2 min

  8. Mar 12

    Helus Pharma Appoints Jill Conwell as Chief People Officer

    Helus Pharma appoints Jill Conwell, a seasoned leader in the life sciences industry, to drive talent strategy and organizational development. Visit the company's newsroom for details.

    1 min
See All (57)

About

Explore the emerging world of psychedelics with the 'NewsRamp Psychedelics Podcast.' This podcast delivers the latest news and insights from NewsRamp.com, focusing on research developments, therapeutic applications, and regulatory changes in the psychedelics field. Stay informed on the groundbreaking advancements in this evolving industry.

Information

More From NewsRamp.com